Member access

4-Traders Homepage  >  Shares  >  Toronto Stock Exchange  >  Cardiome Pharma Corp.    COM   CA14159U3010

 SummaryChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
12/15/2014 12/16/2014 12/17/2014 12/18/2014 12/19/2014 Date
10.3 10.41 10.75 10.88 10.68 Last
8273 2783 4728 10795 39859 Volume
-2.83% +1.07% +3.27% +1.21% -1.84% Change
Company
Cardiome Pharma Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of new therapies that will improve the health of patients around the world.Its product BrinavessTM approved in Europe and other territories for the rapid conversion of recent... 
Sector
Pharmaceuticals
Calendar
03/24Earnings Release
More about the company
Surperformance© ratings of Cardiome Pharma Corp.
Trading Rating : Investor Rating :
More Ratings
Chart CARDIOME PHARMA CORP.
Duration : Period :
Cardiome Pharma Corp. Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Full-screen chart
Financials ( CAD)
Sales 2014 36,0 M
EBIT 2014 -13,7 M
Net income 2014 -16,8 M
Debt 2014 -
Yield 2014 -
Sales 2015 38,6 M
EBIT 2015 -12,5 M
Net income 2015 -15,4 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 4,89x
Capi. / Sales 2015 4,56x
Capitalization 176 M
More Financials
Latest news on CARDIOME PHARMA CORP.
2d ago CARDIOME PHARMA : Enters Development And Commercialization Agreement With Edding..
2d ago CARDIOME PHARMA : Enters Development and Commercialization Agreement with Edding..
11/17 CARDIOME PHARMA : Enters Commercialization Agreement With Aspen For Brinavess In..
11/17 CARDIOME PHARMA : Enters Commercialization Agreement with Aspen for BRINAVESS® i..
11/07 CARDIOME PHARMA : Announces Positive Results from the BRINAVESS® Asia-Pacific Ph..
11/07 CARDIOME PHARMA : Submits BRINAVESS® Reimbursement Dossier to Italian Authoritie..
11/07 CARDIOME PHARMA : Reports Third Quarter 2014 Financial Results
10/31 CARDIOME PHARMA : to Hold Third Quarter 2014 Financial Results Conference Call o..
More news
Sector news
38m ago MERCK : buys new-cancer-drug firm
8h ago Fear factor fades as global M&A hits seven-year high
1d ago AstraZeneca CEO says new Pfizer bid unlikely - Swedish daily DI
More sector news


Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF